Abstract-To investigate whether endothelin-A receptors and nitric oxide modulate renal hemodynamics in man under angiotensin II receptor-1 blockade, 6 healthy volunteers, on a 240 mmol Na diet, underwent 4 separate renal hemodynamic measurements, in 3 of which endothelin-A blocker BQ-123 0.2 nmol ⅐ kg ⅐ min Ϫ1 was infused for 90 minutes after pretreatment with either placebo, telmisartan 1 mg ⅐ kg ⅐ day Ϫ1 for 3 days, or telmisartan as well, but with co-infusion of both BQ-123 and N G -nitro-L-arginine methylester 0.5 g ⅐ kg ⅐ min Ϫ1 . A fourth infusion was made with N G -nitro-L-arginine methylester alone. No change followed infusion of either N G -nitro-L-arginine methylester alone or BQ-123 alone. With BQ-123 after telmisartan, renal blood flow rose from 916Ϯ56 mL ⅐ min Ϫ1 ⅐ 1.73 m 2 to 1047Ϯ51.2 (PϽ0.001), and renal vascular resistances fell from 89Ϯ7 mm Hg ⅐ min ⅐ L Ϫ1 to 74Ϯ4 (PϽ0.001). These changes were fully abolished by the co-infused N G -nitro-L-arginine methylester. Infusion of BQ-123, devoid of renal hemodynamic effects at baseline, produces significant renal vasodilation when angiotensin II receptors are blocked, indicating an increasing renal hemodynamic role of endothelin-A-receptor activity. Because such a vasodilation is prevented by nonvasoconstricting microdoses of N G -nitro-L-arginine methylester, nitric oxide-endothelin balance controls substantially renal hemodynamics under angiotensin II blockade. These findings are consistent with a rationale of the association of endothelin-A blockers with angiotensin II blockers or angiotensin-converting enzyme inhibitors in treating nitric oxide-deficient conditions such as arterial hypertension, heart failure, and chronic renal diseases. Key Words: angiotensin II Ⅲ nitric oxide Ⅲ endothelin Ⅲ kidney Ⅲ hemodynamics Ⅲ L-NAME Ⅲ receptors, endothelin H emodynamic control in both systemic circulation and kidney results physiologically from a balance of opposing vasodilator systems such as nitric oxide (NO) and prostaglandins, and vasoconstrictor systems. 1 These latter include, besides sympathetic nervous system, the 2 potent peptide vasoconstrictors angiotensin II (Ang II) and endothelin-1 (ET-1), 1 this latter being the predominant isoform of endothelin family expressed in human vasculature. 2 Vasoactive properties of ET-1 are mediated by 2 receptor subtypes, ET A and ET B , both leading to vasoconstriction in vascular smooth muscle cells, whereas activation of ET B in endothelial cells may cause vasodilation through the release of prostacyclin and NO. 2,3 At the kidney level, however, studies in both dogs 4,5 and humans 6,7,8 have indicated the ET A receptor as the main mediator of the vasoconstrictor effect of ET-1.A considerable body of evidence has shown that ET-1, although it is the most potent endogenous vasoconstrictor, assumes a major hemodynamic role and contributes to the end-organ damage, mainly under experimental and clinical pathophysiological conditions. 2,3 Furthermore, a number of interactions have been recognized between Ang II and ET...